Lexaria Updates Financial Position with Australian Tax Refund and Institutional Financing
News related to:Lexaria Bioscience Corp · 4 min read
Lexaria Bioscience Corp, a global innovator in drug delivery platforms, has announced a significant update to its financial position. The company has secured a strong cash position following the receipt of an Australian tax refund and a recent institutional financing round. The combined net proceeds from these two sources amounted to US$7.9 million, bringing the company's total cash on hand to approximately US$4.60 per share.
According to Rich Christopher, CEO of Lexaria Bioscience Corp, the company is currently in a strong financial position.
The institutional financing round was priced at US$12.92 per share, raising a total of US$7.9 million. This, combined with the company's pre-existing cash balance, has extended Lexaria's cash runway through 2027.
Lexaria Bioscience Corp operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 66 patents granted and additional patents pending worldwide. The company's DehydraTECH™ platform technology is designed to improve the way a wide variety of drugs enter the bloodstream, always through oral delivery. The technology has repeatedly demonstrated the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood-brain barrier.
The company has made significant progress on its business development front and expects to spend less of its own resources to fund R&D efforts in 2027.
Lexaria will have progress updates on its ongoing 2026 R&D programs soon and will also provide guidance towards its 2027 R&D programs now that the financing activities are complete and budgets can be assembled. The company currently has only 2.1 million shares issued and outstanding, and the US$7.9 million in fresh new capital plus its pre-existing cash balance represents approximately US$4.60 per share in current cash on hand.
About Lexaria Bioscience Corp & DehydraTECH DehydraTECH™ is Lexaria’s patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 66 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS This press release includes forward-looking statements. These statements may be identified by words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the satisfaction of customary closing conditions, the intended use of proceeds from the offering, the anticipated closing of the offering, the Company’s ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company’s ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company’s public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.